Following the recent joint statement from ATAGI and the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ), RACGP confirms that almost anyone over the age of 50 can safely receive the AstraZeneca vaccine. The statement also clarifies that the rare blood clotting condition that has been linked with the use of AstraZeneca’s vaccine in some groups – Huyết khối với Hội chứng giảm tiểu cầu (TTS) – can now be treated effectively.
The latest release also confirms that the risk of TTS is not likely to be increased in people with the following conditions (and that over-50s in these groups can still get vaccinated with AstraZeneca):
- History of blood clots in typical sites
- Increased clotting tendency that is not immune mediated
- Family history of blood clots
- History of ischaemic heart disease or stroke
- Current or past thrombocytopenia (low platelet count)
- Those receiving anticoagulation therapy
Furthermore, the ATAGI/THANZ statement also reports that UK data suggest the risk of TTS is much lower following a second dose, with only 15 cases reported to date out of nine million administered, translating to an estimated rate of 1.7 cases per million doses.
Please refer to the article and statement in full in the following link:
RACGP – Australian authorities update side effect advice on AstraZeneca vaccine